HRS 2017: First ever nasal spray used to treat rapid heart rate condition

Data from a 100-patient clinical trial showed that a fast-acting nasal spray therapy, etripamil, was effective at stopping a common rapid heart rate condition, researchers said today at the annual Heart Rhythm Society conference in Chicago. Paroxysmal supraventricular tachycardia is traditionally treated with adenosine, calcium channel blockers or beta blockers, which is administered using an IV in a clinical setting. There are no available treatments that can be administered by a patient at home. Get the full story at our sister site, Drug Delivery Business News. The post HRS 2017: First ever nasal spray used to treat rapid heart rate condition appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Cardiovascular Clinical Trials Drug-Device Combinations milestonepharmaceutical Source Type: news